Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YL211 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- MediLink Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
YL211 + pembrolizumab is an investigational combination therapy consisting of YL211, a next-generation antibody-drug conjugate (ADC), and pembrolizumab, a programmed cell death protein 1 (PD-1) blocking monoclonal antibody. YL211 targets the c-Mesenchymal Epithelial Transition factor (c-Met), a receptor tyrosine kinase often overexpressed in various cancers, and utilizes MediLink Therapeutics' proprietary Tumor Microenvironment Activable LINker-payload (TMALIN®) platform to deliver a cytotoxic payload directly to tumor cells. Pembrolizumab is a well-established immune checkpoint inhibitor that enhances the body's immune response against cancer by preventing the PD-1/PD-L1 interaction. This combination is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors, including non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC), to explore potential synergistic effects between targeted cytotoxicity and immune activation.
- Other names
- YL211 plus pembrolizumabYL-211 plus pembrolizumabYL 211 plus pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TOP1 (DNA Topoisomerase I)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on YL211 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YL211 + pembrolizumab.